Komal Jhaveri, MD, clinical director for early drug development service at Memorial Sloan Kettering Cancer Center, and Julie Nangia, MD, medical director of breast oncology at Baylor College of Medicine, discuss a randomized phase 3 study of datopotamab deruxtecan vs chemotherapy — how does this trial change our treatment algorithm?
Get email updates from SABCSMeetingNews.org
Subscribe to get regular news updates from SABCS.org and SABCS Meeting News.